Nordic 8 - A Phase II Trial
Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial
Sponsor: Merck Serono International SA
Listed as NCT01867697, this PHASE2 trial focuses on Metastatic Colorectal Cancer and remains completed. Sponsored by Merck Serono International SA, it has been updated 9 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Sep 2020 — Nov 2020 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Sep 2018 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Serono International SA
- Per Pfeiffer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Bergen, Norway , Copenhagen, Denmark , Esbjerg, Denmark , Herlev, Denmark , Herning, Denmark , Næstved, Denmark , Odense, Denmark , Roskilde, Denmark and 2 more locations